Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic

Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O […]

Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic.

Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of treatment retention and fewer hospital encounters compared to 12 weeks of the treatment.

According to a news release, prior publications of real-world use showed that 12 weeks of reSET-O treatment (a single prescription) associates with increased retention, reduced substance use, a reduction in overall healthcare costs and improved quality-adjusted life-year gains.

The analysis covered 3,817 patients with OUD across 12 states in the U.S., with a cohort of 643 patients prescribed a second 12-week “refill” for a total treatment duration of 24 weeks. In that cohort, 94.4% met the responder rate of being abstinent for at least 80% of the weeks of treatment and 91.4% of patients were retained in treatment at the end of the second prescription period.

Patients treated for 24 weeks had an additional 27% decrease in healthcare utilization rates compared to those with 12 weeks of treatment.

“We’ve previously found that 12-weeks of reSET-O treatment (one prescription) has high rates of patient use and the potential to enhance health outcomes and reduce healthcare costs. This new analysis, the first real-world evaluation of patients treated for 24 consecutive weeks with reSET-O, demonstrates that patients both engage with a refill prescription, and that the engagement is associated with improvements in clinical and health economic outcomes, including abstinence, retention in treatment, and reduction in emergency room, in-patient, and intensive care unit stays compared to patients not treated, as well as those treated for 12 weeks,” Pear Therapeutics CMO Dr. Yuri Maricich said in the release. “As OUD overdose rates and OUD incidence worsens across the country, these findings are timely as they continue to support reSET-O as a tool help patients stay in recovery, while potentially reducing sizeable healthcare spend.”

Original Article: (